story of the week
Efficacy and Safety of Intravitreal Aflibercept 8 mg in Patients With Neovascular AMD
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial
Lancet 2024 Mar 07;[EPub Ahead of Print], P Lanzetta, JF Korobelnik, JS Heier, S Leal, FG Holz, WL Clark, D Eichenbaum, T Iida, S Xiaodong, AJ Berliner, A Schulze, T Schmelter, U Schmidt-Ott, X Zhang, R Vitti, KW Chu, K Reed, R Rao, R Bhore, Y Cheng, W Sun, B Hirshberg, GD Yancopoulos, TY WongFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.